BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26285159)

  • 1. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma.
    Zhao L; Jiang R; Xu M; Zhu P; Mo XM; Wang N; Chen GG; Liu ZM
    Clin Endocrinol (Oxf); 2016 May; 84(5):748-55. PubMed ID: 26285159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
    Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
    Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
    Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of HIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Dong CR; Jiang R; Tang C; Yang L; Jiang QF; Chen GG; Liu ZM
    Int J Clin Exp Pathol; 2014; 7(1):322-30. PubMed ID: 24427353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
    Kim YS; Kim JS; Bae JS; Park WC
    World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
    Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
    J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
    Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
    Li W; Ming H; Sun D; Li W; Wang D; Zhang G; Tan J
    Pathol Res Pract; 2017 Mar; 213(3):183-188. PubMed ID: 28214213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
    Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
    Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation.
    Park WS; Chung KW; Young MS; Kim SK; Lee YJ; Lee EK
    Anticancer Res; 2013 Oct; 33(10):4357-64. PubMed ID: 24123003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.
    Sykorova V; Dvorakova S; Ryska A; Vcelak J; Vaclavikova E; Laco J; Kodetova D; Kodet R; Cibula A; Duskova J; Hlobilkova A; Astl J; Vesely D; Betka J; Hoch J; Smutny S; Cap J; Vlcek P; Novak Z; Bendlova B
    J Endocrinol Invest; 2010 May; 33(5):318-24. PubMed ID: 20009493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.